[go: up one dir, main page]

AR102464A1 - Célula cho recombinante, cultivo a gran escala que la comprende y composición que comprende un complejo pentamérico de citomegalovirus (cmv) producido mediante los mismos - Google Patents

Célula cho recombinante, cultivo a gran escala que la comprende y composición que comprende un complejo pentamérico de citomegalovirus (cmv) producido mediante los mismos

Info

Publication number
AR102464A1
AR102464A1 ARP150103502A ARP150103502A AR102464A1 AR 102464 A1 AR102464 A1 AR 102464A1 AR P150103502 A ARP150103502 A AR P150103502A AR P150103502 A ARP150103502 A AR P150103502A AR 102464 A1 AR102464 A1 AR 102464A1
Authority
AR
Argentina
Prior art keywords
fragment
cho
cmv
cell
cho cell
Prior art date
Application number
ARP150103502A
Other languages
English (en)
Inventor
Wen Yingxia
Laux Holger
Hofmann Irmgard
Ciferri Claudio
Carfi Andrea
Lilja Anders
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Publication of AR102464A1 publication Critical patent/AR102464A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
    • C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16151—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Reproductive Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Una célula CHO recombinante, que comprende: una o más secuencias de polinucleótidos que codifican complejo pentamérico de citomegalovirus (CMV), en las que dicho complejo pentamérico comprende: gH o un fragmento de la misma que forma complejos, gL o un fragmento de la misma que forma complejos, pUL128 o un fragmento de la misma que forma complejos, pUL130 o un fragmento de la misma que forma complejos, y pUL131 o un fragmento de la misma que forma complejos:,en la que dicha una o más secuencias de polinucleótidos se integran en el ADN genómico de dicha célula CHO. Dicha célula CHO es una célula CHO-K1, CHO-DUXB11, célula CHO-DG44, o célula CHO-S. Cultivo a gran escala que comprende la célula CHO descrita, en donde dicho cultivo tiene un volumen de al menos 20 litros. El cultivo a gran escala tiene un rendimiento de complejo pentamérico de CMV de al menos 0,05 g/I. Una composición que comprende un complejo pentamérico de citomegalovirus (CMV), en donde dicho complejo pentamérico comprende: gH o un fragmento de la misma que forma complejos, gL o un fragmento de la misma que forma complejos. pUL128 o un fragmento de la misma que forma complejos, pUL130 o un fragmento de la misma que forma complejos, y pUL131 o un fragmento de la misma que forma complejos, y en la que dicho complejo pentamérico se produce mediante la célula CHO, o el cultivo a gran escala.
ARP150103502A 2014-10-31 2015-10-29 Célula cho recombinante, cultivo a gran escala que la comprende y composición que comprende un complejo pentamérico de citomegalovirus (cmv) producido mediante los mismos AR102464A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14191385.5A EP3015475A1 (en) 2014-10-31 2014-10-31 Mammalian cells expressing cytomegalovirus antigens

Publications (1)

Publication Number Publication Date
AR102464A1 true AR102464A1 (es) 2017-03-01

Family

ID=51844603

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP150103502A AR102464A1 (es) 2014-10-31 2015-10-29 Célula cho recombinante, cultivo a gran escala que la comprende y composición que comprende un complejo pentamérico de citomegalovirus (cmv) producido mediante los mismos

Country Status (19)

Country Link
US (1) US10414802B2 (es)
EP (2) EP3015475A1 (es)
JP (1) JP6688297B2 (es)
CN (1) CN107075486B (es)
AR (1) AR102464A1 (es)
BE (3) BE1023364B1 (es)
BR (1) BR112017008827A2 (es)
CA (1) CA2964859C (es)
CY (1) CY1123405T1 (es)
DK (1) DK3212660T3 (es)
ES (1) ES2799735T3 (es)
HR (1) HRP20200932T1 (es)
HU (1) HUE049356T2 (es)
LT (1) LT3212660T (es)
MX (1) MX387400B (es)
PL (1) PL3212660T3 (es)
PT (1) PT3212660T (es)
SI (1) SI3212660T1 (es)
WO (1) WO2016067239A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2878344A1 (en) 2012-07-06 2014-01-09 Novartis Ag Complexes of cytomegalovirus proteins
EP3052106A4 (en) 2013-09-30 2017-07-19 ModernaTX, Inc. Polynucleotides encoding immune modulating polypeptides
EP4332231A3 (en) * 2014-04-29 2024-05-29 Novartis AG Novel vertebrate cells and methods for recombinantly expressing a polypeptide of interest
EP3048114A1 (en) 2015-01-22 2016-07-27 Novartis AG Cytomegalovirus antigens and uses thereof
WO2017070613A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Human cytomegalovirus vaccine
MA46584A (fr) 2016-10-21 2019-08-28 Modernatx Inc Vaccin contre le cytomégalovirus humain
CN107723276B (zh) * 2017-11-02 2021-08-13 上海交通大学 一种稳定高表达目标产物的细胞株的构建方法和试剂盒
IL278418B2 (en) 2018-05-04 2024-01-01 Spybiotech Ltd Vaccine composition
AU2019397719B2 (en) * 2018-12-10 2023-11-09 Km Biologics Co., Ltd. Vaccine for preventing or treating congenital infection with cytomegalovirus
WO2021156720A1 (en) * 2020-02-05 2021-08-12 Novartis Ag Cho cell expressing il-15 heterodimers
US11406703B2 (en) 2020-08-25 2022-08-09 Modernatx, Inc. Human cytomegalovirus vaccine
US20240024455A1 (en) * 2020-12-02 2024-01-25 Seqirus Inc. Multicistronic rna vaccines and uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
AU635844B2 (en) 1989-11-06 1993-04-01 Cell Genesys, Inc. Production of proteins using homologous recombination
US5589392A (en) 1991-01-14 1996-12-31 Stratagene Nucleic acid construct encoding a nuclear transport peptide operatively linked to an inducible promoter
US7704510B2 (en) 2006-06-07 2010-04-27 The Trustees Of Princeton University Cytomegalovirus surface protein complex for use in vaccines and as a drug target
KR102162111B1 (ko) * 2010-10-11 2020-10-07 노파르티스 아게 항원 전달 플랫폼
CA2878344A1 (en) 2012-07-06 2014-01-09 Novartis Ag Complexes of cytomegalovirus proteins
CN104884467A (zh) 2012-12-18 2015-09-02 诺华股份有限公司 在遗传修饰的哺乳动物细胞中生产治疗性蛋白质
CA2934412C (en) 2013-12-20 2024-02-20 Novartis Ag Novel eukaryotic cells and methods for recombinantly expressing a product of interest
CA2934411C (en) 2013-12-20 2022-05-03 Novartis Ag Novel eukaryotic cells and methods for recombinantly expressing a product of interest
WO2015165480A1 (en) * 2014-04-30 2015-11-05 Institute For Research In Biomedicine Human cytomegalovirus vaccine compositions and method of producing the same
EP4332231A3 (en) 2014-04-29 2024-05-29 Novartis AG Novel vertebrate cells and methods for recombinantly expressing a polypeptide of interest

Also Published As

Publication number Publication date
BE1023841A1 (fr) 2017-08-09
PL3212660T3 (pl) 2020-10-05
EP3015475A1 (en) 2016-05-04
EP3212660A1 (en) 2017-09-06
WO2016067239A1 (en) 2016-05-06
BE1023841B1 (fr) 2017-08-10
US10414802B2 (en) 2019-09-17
MX387400B (es) 2025-03-18
SI3212660T1 (sl) 2020-07-31
CY1123405T1 (el) 2021-12-31
DK3212660T3 (da) 2020-06-15
HRP20200932T1 (hr) 2020-09-18
BE1023840B1 (fr) 2017-08-10
ES2799735T3 (es) 2020-12-21
US20170362278A1 (en) 2017-12-21
MX2017005661A (es) 2017-06-26
HUE049356T2 (hu) 2020-09-28
CA2964859A1 (en) 2016-05-06
CN107075486B (zh) 2021-06-22
PT3212660T (pt) 2020-06-23
BE1023364A1 (fr) 2017-02-20
EP3212660B1 (en) 2020-03-25
JP2017534283A (ja) 2017-11-24
LT3212660T (lt) 2020-07-10
JP6688297B2 (ja) 2020-04-28
BE1023840A1 (fr) 2017-08-09
CN107075486A (zh) 2017-08-18
BR112017008827A2 (pt) 2018-03-27
CA2964859C (en) 2023-04-04
BE1023364B1 (fr) 2017-02-20

Similar Documents

Publication Publication Date Title
AR102464A1 (es) Célula cho recombinante, cultivo a gran escala que la comprende y composición que comprende un complejo pentamérico de citomegalovirus (cmv) producido mediante los mismos
MX2017004919A (es) Proteinas quimericas insecticidas novedosas toxicas o inhibidoras de plagas de lepidopteros.
MX2018007290A (es) Metodos y composiciones para expresion de acido ribonucleico (arn) guia basada en polimerasa ii (pol-ii).
MX2017007538A (es) Sintesis de ácido nucleíco de volúmen pequeño, alta eficiencia.
UA120923C2 (uk) Молекула нуклеїнової кислоти, яка кодує капсидний протеїн aav5
EA201791343A1 (ru) Композиции и способы для конструирования вирусного генома in vitro
EA201890360A1 (ru) Соединение, нацеленное на ил-23a и фактор активации в-лимфоцитов (baff), и его применение
MX2017015668A (es) Microorganismos recombinante para la produccion mejorada de quimicos finos.
EA033293B1 (ru) Рекомбинантный микроорганизм, экспрессирующий аналог авермектина, и его применение
WO2016012445A3 (en) Process for the purification of poliovirus from cell cultures
CO2017006736A2 (es) Supresión de arni parental de gen hunchback para el control de las plagas de hemípteros
MX2021013879A (es) Variantes de lipasa y polinucleotidos que las codifican.
PH12019500299A1 (en) Caisson block construction method and caisson block structure
CO2017009163A2 (es) Moléculas de ácido nucleico de arn polimerasa ii33 para el control de plagas de insectos
UY40808A (es) Molécula de adn recombinante aislada con actividad reguladora de genes y método para producir una planta transgénica
CL2017001523A1 (es) Supresion parental rnai del gen hunchback para el control de plagas de coleopteros
CL2017001522A1 (es) Supresion parental rnai del gen kruppel para el control de plagas de coleopteros
MX2023009350A (es) Plantas modificadas que contienen una combinacion de genes de apirasa y metodo para obtener plantas modificadas con combinacion de genes de apirasa.
CL2017002266A1 (es) Arn polimeriza ii215 moléculas de ácido nucleico para controlar plaga de insectos.
RU2015154352A (ru) Генетическая конструкция для экспрессии генов в клетках насекомого polypedilum vanderplanki
MX392243B (es) Control biológico de virus vegetales.
CO2017003557A2 (es) Moleculas de acido nucleico gho/sec24b2 y sec24b1 para controlar plagas de coleopteros y hemipteros
Khan et al. Hermite–Laguerre matrix polynomials and generating relations
Строкова et al. Numerical modeling of influence of soil mass reinforcement with cement-sand grouting on foundation deformation
CO2017006535A2 (es) Supresión por iarn parental del gen kruppel para el control de las plagas de hemípteros

Legal Events

Date Code Title Description
FA Abandonment or withdrawal